US5411740A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Transdermal administration of oxybutynin
Assignee: Alza Corp
•
Filing: 1994-02-08
•
Granted: 1995-05-02
•
Expires: 2014-02-08
Abstract
Abstract The present invention is directed to the transdermal administration of oxybutynin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in oxybutynin- and permeation enhancer-transmitting relation with the skin site. The matrix contains sufficient amounts of a permeation enhancer and of oxybutynin, in combination, to continuously administer to the skin for a predetermined period of time the oxybutynin to provide an effective therapeutic result. The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of oxybutynin together with a skin permeation-enhancing amount of a suitable permeation enhancer.
Inventors
- 👤 Eun S. Lee
- 👤 Diane E. Nedberge
- 👤 Su I. Yum
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 17:55
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K31/21; A61K31/215; A61K31/216; A61K47/00; A61K47/06; A61K47/08; A61K47/14; A61K9/0012; A61K9/0014; A61K9/7084; A61P; A61P13/00; A61P13/02; A61P15/00; A61P25/00
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
96 words
A device for the transdermal administration, at a therapeutically effective rate, of oxybutynin, which device comprises: (a) a reservoir consisting essentially of a therapeutically effective amount of an oxybutynin base, a skin permeation-enhancing amount of a monoglyceride or a mixture of monoglycerides of fatty acids with a total monoesters content of at least 51%, and ethylene vinyl acetate copolymer having from about 9% to about 60% vinyl acetate; (b) a backing on the skin-distal surface of the reservoir; and (c) an adhesive means for maintaining the reservoir in oxybutynin- and permeation enhancer-transmitting relation with the skin.
Claim 2
Independent Claim
96 words
A device for the transdermal administration, at a therapeutically effective rate, of oxybutynin, which device comprises: (a) a reservoir consisting essentially of a therapeutically effective amount of an oxybutynin base, a skin permeation-enhancing amount of a monoglyceride or a mixture of monoglycerides of fatty acids with a total monoesters content of at least 51%, and ethylene vinyl acetate copolymer having from about 9% to about 60% vinyl acetate; (b) a backing on the skin-distal surface of the reservoir; and (c) an adhesive means for maintaining the reservoir in oxybutynin- and permeation enhancer-transmitting relation with the skin.
Claim 3
Dependent Claim
18 words
A device according to claim 1 wherein the permeation enhancer is glycerol monooleate, glycerol monolaurate or glycerol monolinoleate.
Claim 4
Dependent Claim
28 words
A device according to claim 1 wherein the oxybutynin is administered through the skin at a rate of at least 0.08 mg/hour for a predetermined period of time.
Claim 5
Dependent Claim
31 words
A device according to claim 1 wherein the oxybutynin is administered through the skin at a permeation rate of at least 12 μg/cm 2 /hr for a predetermined period of time.
Claim 6
Dependent Claim
14 words
A device according to claim 1 wherein the backing is permeable to water vapor.
Claim 7
Dependent Claim
13 words
A device according to claim 1 wherein the permeation enhancer is glycerol monooleate.
Claim 8
Dependent Claim
30 words
A device according to claim 5 wherein the means for maintaining the reservoir in relation with the skin comprises an in-line adhesive layer on the skin-proximal surface of the reservoir.
Claim 9
Independent Claim
138 words
A device for the transdermal administration at a therapeutically effective rate, of oxybutynin, which device comprises: (a) a first reservoir consisting essentially of a therapeutically effective amount of an oxybutynin base, a skin permeation-enhancing amount of a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51%, and ethylene vinyl acetate copolymer having from about 9% to about 60% vinyl acetate; (b) a second reservoir comprising an excess of the monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51% (c) a rate-controlling membrane between the first reservoir and the second reservoir; (d) a backing on the skin-distal surface of the second reservoir; and (e) an adhesive means for maintaining the first and second reservoirs in oxybutynin- and permeation enhancer-transmitting relation with the skin.
Claim 10
Independent Claim
138 words
A device for the transdermal administration at a therapeutically effective rate, of oxybutynin, which device comprises: (a) a first reservoir consisting essentially of a therapeutically effective amount of an oxybutynin base, a skin permeation-enhancing amount of a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51%, and ethylene vinyl acetate copolymer having from about 9% to about 60% vinyl acetate; (b) a second reservoir comprising an excess of the monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51% (c) a rate-controlling membrane between the first reservoir and the second reservoir; (d) a backing on the skin-distal surface of the second reservoir; and (e) an adhesive means for maintaining the first and second reservoirs in oxybutynin- and permeation enhancer-transmitting relation with the skin.
Claim 11
Dependent Claim
28 words
A device according to claim 8 wherein the oxybutynin is administered through the skin at a rate of at least 0.08 mg/hour for a predetermined period of time.
Claim 12
Dependent Claim
31 words
A device according to claim 8 wherein the oxybutynin is administered through the skin at a permeation rate of at least 12 μg/cm 2 /hr for a predetermined period of time.
Claim 13
Dependent Claim
14 words
A device according to claim 8 wherein the backing is permeable to water vapor.
Claim 14
Dependent Claim
31 words
A device according to claim 8 wherein the means for maintaining the reservoirs in relation with the skin comprises an in-line adhesive layer on the skin-proximal surface of the first reservoir.
Claim 15
Dependent Claim
29 words
A device according to claim 8 wherein the first reservoir also is an adhesive layer which functions as the means for maintaining the reservoirs in relation with the skin.
Claim 16
Dependent Claim
18 words
A device according to claim 8 wherein the permeation enhancer is glycerol monooleate, glycerol monolaurate or glycerol monolinoleate.
Claim 17
Independent Claim
123 words
A method for treating neurogenic bladder disorders, the method comprising the step of placing an oxybutynin transdermal delivery device onto the skin of a person, the oxybutynin transdermal delivery device comprising: (a) a reservoir consisting essentially of oxybutynin base in an amount sufficient to provide treatment of symptoms of a neurogenic bladder for a predetermined period of time, a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51% in a skin permeation-enhancing amount, and ethylene vinyl acetate copolymer having from about 9% to about 60% vinyl acetate; (b) a backing on the skin-distal surface of the reservoir; and (c) an adhesive means for maintaining the reservoir in oxybutynin- and permeation enhancer-transmitting relation with the skin.
Claim 18
Independent Claim
123 words
A method for treating neurogenic bladder disorders, the method comprising the step of placing an oxybutynin transdermal delivery device onto the skin of a person, the oxybutynin transdermal delivery device comprising: (a) a reservoir consisting essentially of oxybutynin base in an amount sufficient to provide treatment of symptoms of a neurogenic bladder for a predetermined period of time, a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51% in a skin permeation-enhancing amount, and ethylene vinyl acetate copolymer having from about 9% to about 60% vinyl acetate; (b) a backing on the skin-distal surface of the reservoir; and (c) an adhesive means for maintaining the reservoir in oxybutynin- and permeation enhancer-transmitting relation with the skin.
Claim 19
Dependent Claim
18 words
A method according to claim 15 wherein the permeation enhancer is glycerol monooleate, glycerol monolaurate or glycerol monolinoleate.
Claim 20
Dependent Claim
28 words
A method according to claim 15 wherein the oxybutynin is administered through the skin at a rate of at least 0.08 mg/hour for the predetermined period of time.
Claim 21
Dependent Claim
31 words
A method according to claim 15 wherein the oxybutynin is administered through the skin at a permeation rate of at least 12 μg/cm 2 /hr for a predetermined period of time.
Claim 22
Dependent Claim
14 words
A method according to claim 15 wherein the backing is permeable to water vapor.
Claim 23
Dependent Claim
13 words
A method according to claim 15 wherein the permeation enhancer is glycerol monooleate.
Claim 24
Dependent Claim
30 words
A method according to claim 20 wherein the means for maintaining the reservoir in relation with the skin comprises an in-line adhesive layer on the skin-proximal surface of the reservoir.
Claim 25
Independent Claim
166 words
A method for treating neurogenic bladder disorders, the method comprising the step of placing a oxybutynin transdermal delivery device onto the skin of a person, the oxybutynin transdermal delivery device comprising: (a) a first reservoir consisting essentially of oxybutynin base in an amount sufficient to provide treatment of symptoms of a neurogenic bladder for a predetermined period of time, a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51% in a skin permeation-enhancing amount, and ethylene vinyl acetate copolymer having from about 9% to about 60% vinyl acetate; (b) a second reservoir comprising an excess of the monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51% (c) a rate-controlling membrane between the first reservoir and the second reservoir; (d) a backing on the skin-distal surface of the second reservoir; and (e) an adhesive means for maintaining the first and second reservoirs in oxybutynin- and permeation enhancer-transmitting relation with the skin.
Claim 26
Independent Claim
166 words
A method for treating neurogenic bladder disorders, the method comprising the step of placing a oxybutynin transdermal delivery device onto the skin of a person, the oxybutynin transdermal delivery device comprising: (a) a first reservoir consisting essentially of oxybutynin base in an amount sufficient to provide treatment of symptoms of a neurogenic bladder for a predetermined period of time, a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51% in a skin permeation-enhancing amount, and ethylene vinyl acetate copolymer having from about 9% to about 60% vinyl acetate; (b) a second reservoir comprising an excess of the monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51% (c) a rate-controlling membrane between the first reservoir and the second reservoir; (d) a backing on the skin-distal surface of the second reservoir; and (e) an adhesive means for maintaining the first and second reservoirs in oxybutynin- and permeation enhancer-transmitting relation with the skin.
Claim 27
Dependent Claim
28 words
A method according to claim 22 wherein the oxybutynin is administered through the skin at a rate of at least 0.08 mg/hour for a predetermined period of time.
Claim 28
Dependent Claim
30 words
A method according to claim 22 wherein oxybutynin is administered through the skin at a permeation rate of at least 12 μg/cm 2 /hr for a predetermined period of time.
Claim 29
Dependent Claim
14 words
A method according to claim 22 wherein the backing is permeable to water vapor.
Claim 30
Dependent Claim
31 words
A method according to claim 22 wherein the means for maintaining the reservoirs in relation with the skin comprises an inline adhesive layer on the skin-proximal surface of the first reservoir.
Claim 31
Dependent Claim
29 words
A method according to claim 22 wherein the first reservoir also is an adhesive layer which functions as the means for maintaining the reservoirs in relation with the skin.
Claim 32
Dependent Claim
18 words
A device according to claim 22 wherein the permeation enhancer is glycerol monooleate, glycerol monolaurate or glycerol monolinoleate.
References Cited (Backward Citations)
GB1001949A
Cited
US3371683A
Cited
US3598122A
Cited
US3598123A
Cited
US3797494A
Cited
US3598122B1
Cited
US4405616A
Cited
US4031894A
Cited
US4130643A
Cited
US4130667A
Cited
US4335115A
Cited
US4201211A
Cited
US4299826A
Cited
US4286592A
Cited
US4314557A
Cited
US4379454A
Cited
US4343798A
Cited
US4849226A
Cited
US4435180A
Cited
US4474845A
Cited
US4559222A
Cited
US4704282A
Cited
US4588580A
Cited
US4588580B2
Cited
US4588580B1
Cited
US4568343A
Cited
US4573995A
Cited
US4645502A
Cited
BE902605A
Cited
EP0250125A2
Cited
US4784857A
Cited
US4908027A
Cited
US4746515A
Cited
US4816258A
Cited
US4865848A
Cited
US4788062A
Cited
US4940586A
Cited
US5071656A
Cited
US4820720A
Cited
US4928680A
Cited
US4943435A
Cited
US4849224A
Cited
US4863738A
Cited
US4994278A
Cited
US5004610A
Cited
JPH0499719A
Cited
WO1992010231A1
Cited
JPH04266821A
Cited
JPH04273818A
Cited
WO1992020377A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-05-01 | 1998-10-31 | 1999-05-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-05-01 | 2002-10-31 | 2003-05-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-05-01 | 2006-10-31 | 2007-05-02 | $7700.00 | Window Closed / Lapsed |